HCM: HUTCHMED (China) Ltd insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
56 institutions reported holding $45.67M of HUTCHMED (China) Ltd on Form 13F (54 the quarter before). 8 opened a new position and 5 sold out. Shares held by institutions: same.
| Largest holders | Shares | Value |
|---|---|---|
| SCHRODER INVESTMENT MANAGEMENT GROUP | 1,477,494 | $15.82M |
| Allianz Asset Management GmbH | 674,511 | $7.26M |
| STATE STREET CORP | 313,611 | $3.37M |
| AIA Group Ltd | 291,229 | $3.13M |
| M&G PLC | 242,791 | $2.67M |
| Amundi | 204,385 | $2.20M |
| JANE STREET GROUP, LLC | 194,472 | $2.09M |
| RENAISSANCE TECHNOLOGIES LLC | 130,200 | $1.40M |
| BNP PARIBAS FINANCIAL MARKETS | 104,425 | $1.12M |
| XY Capital Ltd | 104,130 | $1.12M |
Clinical trial readouts
1 Phase 2 or 3 trials by HUTCHMED (China) Ltd with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-08-28 | fruquintinib+sintilimab | Advanced Renal Cell Carcinoma | Phase 2/3 | 265 | Completed | NCT05522231 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.